Results 201 to 210 of about 53,685 (285)

Clinical Use Patterns and Patient-Reported Experience with Inhaled Levodopa in Routine Practice: A Two-Center Study. [PDF]

Med Sci (Basel)
Delgado Ballestero T, Escalante Arroyo S, Mandrá Noya MA.   +2 more
europepmc   +1 more source

Vitamin B6 Deficiency and Status Epilepticus: A Preventable Cause of Death in People with Parkinson's Disease

Movement Disorders, EarlyView.
Karlo J. Lizarraga, Andres M. Kanner, Anthony E. Lang   +2 more
wiley   +1 more source

Bioengineered microbiotic levodopa therapy improves cognition and reduces pathology in a rat model of Alzheimer's disease

British Journal of Pharmacology, EarlyView.
Background and Purpose Degeneration of the pontine noradrenergic and midbrain dopaminergic systems contributes to cognitive‐behavioural disturbances during the prodromal stages of Alzheimer's disease (AD). We developed a genetically engineered, programmable probiotic Escherichia coli Nissle 1917 strain (EcNrhaL‐DOPA) capable of producing L‐3,4 ...
Mona Abdelhamid, Piyush Padhi, Mahsa Gifani, John S. Beck, Jacob P. Thomas, Gargi Khadse, Catherine Kudela, Gregory J. Phillips, Anumantha G. Kanthasamy, Scott E. Counts   +9 more
wiley   +1 more source

Pharmacokinetic-guided Management of Foslevodopa/Foscarbidopa infusion in <i>PINK1</i>-related Parkinson's disease with neuropsychiatric vulnerability. [PDF]

Clin Park Relat Disord
Okusa S, Shimazu Y, Sakai R, Akiyoshi T, Nukariya T, Nihei Y, Nakahara J, Ohtani H, Seki M.   +8 more
europepmc   +1 more source

A De Novo ATP1A3 p.Arg995His Variant in a Patient With an Adult‐Onset Primary Lateral Sclerosis‐Like Syndrome

Clinical Genetics, EarlyView.
A 43‐year‐old woman developed a progressive adult‐onset upper motor neuron syndrome fulfilling the clinical criteria for primary lateral sclerosis (PLS), with mild cerebellar involvement. Genetic testing identified a de novo ATP1A3 p.Arg995His variant affecting a highly conserved residue within the transmembrane M8 domain.
Pablo Hernandez‐Vitorique, Marta García de Burgos, Ana Campos Villegas, María José Gómez Heredia, Pilar Carbonell Corvillo   +4 more
wiley   +1 more source

Descrição atualizada da paralisia cerebral

Developmental Medicine &Child Neurology, EarlyView.
Resumo A paralisia cerebral (PC) é um termo descritivo amplamente utilizado para um espectro de deficiências motoras causadas por lesão ou malformação cerebral não progressiva ocorrida durante as fases iniciais do desenvolvimento. Avanços recentes nas áreas da genética, de pesquisa em inflamação e em neurofisiologia têm refinado a compreensão ...
Bernard Dan, Peter Rosenbaum, Lucinda Carr, Martin Gough, John Coughlan, Nonyelum Nweke   +5 more
wiley   +1 more source

Initiating levodopa pump therapy: a qualitative study of patient and caregiver perspectives. [PDF]

BMC Nurs
Scharfenort M, Nobrell A, Garon M, Rosqvist K, Paul G, Nilsson MH, Antonini A, Nyholm D, Odin P, Mangrio E.   +9 more
europepmc   +1 more source

Intervention outcomes of children with non‐degenerative dystonia and associated hyperkinetic movement disorders: A scoping review

Developmental Medicine &Child Neurology, EarlyView.
Abstract Aim To identify the outcomes reported in published studies of intervention approaches used with non‐degenerative childhood hyperkinetic movement disorders, including dystonia, dyskinesia, hypertonia, athetosis, chorea, cerebral palsy, involuntary movement, and kernicterus, and map them to the International Classification of Functioning ...
Hortensia Gimeno, Hannah Scott, Rocio Muñoz Sanchez, Alice Doohan, Deepti Chugh, Adrienne Harvey, Kirsty Stewart, Peter Rosenbaum, Grace Stynes, Khamani Edwards, Katherine Knighting   +10 more
wiley   +1 more source

Real-world experience with foslevodopa/foscarbidopa in Germany: therapeutic insights and lessons learned. [PDF]

Neurol Res Pract
Weise D, Warnecke T, Buhmann C, Ebersbach G, Eggers C, Falkenburger B, Höglinger G, Mollenhauer B, Pedrosa D, Südmeyer M, Weiss D, Kassubek J, Jost WH.   +12 more
europepmc   +1 more source